Tyrosine kinase inhibitors such as erlotinib or gefitinib could prolong 5-year survival of metastatic NSCLC patients with EGFR mutation to 14.6% as compared with lower than 5% of nontreated patients [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.